research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata
1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
Search
for
Sort by
Research
420-450 / 1000+ results research Randomized Therapeutic trial for patients with Alopecia Areata .
Topical minoxidil, intralesional steroids, and cryotherapy significantly improve alopecia areata.
research Combination Therapy With CGF and Microneedling‐Assisted Compound Betamethasone for Resistant Alopecia Areata: APilot Study
Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
research Discussion of “A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III” by Andrew G. Chapple and Peter F. Thall
The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
research Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy
Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
research DEFINING THE ROLE OF ABI1 GENE IN PROSTATE CANCER PROGRESSION AND TREATMENT RESISTANCE
The ABI1 gene contributes to prostate cancer progression and treatment resistance.
research Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata
A new mix of anthralin and calcipotriene might help treat severe hair loss.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
research P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
research 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
research Beard hair response in Alopecia Areata Universalis treated with baricitinib
Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program
research BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
research Hormonal Control of Cardiac Action Potential Phase 1 Currents in the Brugada Syndrome
Androgens may increase arrhythmias in Brugada Syndrome, while Finasteride could reduce them.
research Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
research Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study
research Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update
Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
research Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
research A randomized double-blind placebo-controlled clinical trial to evaluate the effect of an Annurca apple supplement formula in androgenic alopecia
The Annurca apple supplement significantly improved hair growth in people with hair loss.